Back to top
more

BioNTech (BNTX)

(Delayed Data from NSDQ)

$111.35 USD

111.35
884,982

+0.05 (0.04%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $111.30 -0.05 (-0.04%) 6:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is a Beat Likely for AstraZeneca (AZN) in Q1 Earnings?

by Zacks Equity Research

AstraZeneca's (AZN) first-quarter results are expected to reflect the impact of strong demand for new drugs as well as coronavirus-led disruption. Investors are likely to focus on COVID-19 vaccine related updates.

Zacks Equity Research

What's in Store for Vertex (VRTX) This Earnings Season?

by Zacks Equity Research

On Vertex's (VRTX) first-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and the company's pipeline progress.

Zacks Equity Research

Pfizer (PFE)/ BioNTech to Supply Extra Comirnaty Doses to EU

by Zacks Equity Research

The European Commission exercises its option to purchase an additional 100 million doses of Pfizer (PFE)/ BioNTech's COVID-19 vaccine, Comirnaty, for EU member states.

Zacks Equity Research

Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra

by Zacks Equity Research

Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.

Zacks Equity Research

Moderna (MRNA) Gives Pipeline Update, to Initiate New Pivotal Study

by Zacks Equity Research

Moderna (MRNA) is developing 14 mRNA-based vaccine candidates in different stages of clinical development. Interim data from ongoing cytomegalovirus and RSV vaccine studies are promising.

Zacks Equity Research

SMART Global, General Motors, Moderna, BioNTech and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

SMART Global, General Motors, Moderna, BioNTech and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

Kinjel Shah headshot

Which Vaccine Maker Will Win the Fight Against COVID-19?

by Kinjel Shah

A comparison between COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX), Moderna's (MRNA), AstraZeneca (AZN) and J&J (JNJ) is inevitable.

Zacks Equity Research

Consumer Price Index Rise 0.6%

by Zacks Equity Research

Consumer Price Index Rise 0.6%

Mark Vickery headshot

CPI +0.6%: Higher, but Not Scary; JNJ Vax on Hold?

by Mark Vickery

Headline CPI last month reached +0.6%, 10 basis points ahead of consensus, and the highest single-month tally since June of 2009.

Zacks Equity Research

BioNTech SE Sponsored ADR (BNTX) Moves 6.7% Higher: Will This Strength Last?

by Zacks Equity Research

BioNTech SE Sponsored ADR (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

J&J's (JNJ) COVID-19 Jab Under EU Review for Rare Blood Clots

by Zacks Equity Research

The European drug regulator's safety committee is conducting a review to asses a link between J&J's (JNJ) COVID-19 vaccine and rare blood clots.

Sweta Jaiswal, FRM headshot

Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus

by Sweta Jaiswal, FRM

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

Zacks Equity Research

AstraZeneca (AZN) COVID-19 Jab May Have Link to Rare Blood Clots

by Zacks Equity Research

European regulators find a possible link between AstraZeneca's (AZN) COVID-19 vaccine and rare blood clot events.

Zacks Equity Research

Dow, Gibraltar Industries, Pfizer, BioNTech and Micron highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Dow, Gibraltar Industries, Pfizer, BioNTech and Micron highlighted as Zacks Bull and Bear of the Day

Zacks Equity Research

Pfizer (PFE)/BioNTech COVID-19 Vaccine 100% Effective in Teens

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) report 100% efficacy for their COVID-19 vaccine in teenagers aged 12 to 15.

Mark Vickery headshot

Dow Dips, Other Markets Up for the Day; Micron (MU) Beats

by Mark Vickery

Micron Technologies (MU), a Zacks Rank #1 (Strong Buy) memory and data storage giant, posted a modest beat on both top and bottom lines in its fiscal Q2 earnings.

Sweta Jaiswal, FRM headshot

ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update

by Sweta Jaiswal, FRM

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

Zacks Equity Research

Company News for Mar 31, 2021

by Zacks Equity Research

Companies in The News Are: BNTX,PYPL,ASO,GME

Zacks Equity Research

J&J (JNJ) COVID-19 Vaccine Gets Conditional Approval in Europe

by Zacks Equity Research

J&J's (JNJ) single-shot COVID-19 vaccine set to be available in Europe from April.

Mark Vickery headshot

Dow Hits New All-Time High Close as Rescue Bill Passes

by Mark Vickery

Expectations are now for a full-throated economic recovery to take hold, which happens to be dovetailing with the reopening of around a dozen states.

Zacks Equity Research

VBI Vaccines (VBIV) Up on Monovalent COVID-19 Vaccine Study

by Zacks Equity Research

VBI Vaccines (VBIV) is developing a monovalent and trivalent COVID-19 vaccines in separate phase I/II studies.

Zacks Equity Research

Pfizer's (PFE) Vaccine Seems Potent Against COVID-19 Strains

by Zacks Equity Research

Pfizer's (PFE) coronavirus vaccine seems to neutralize the more contagious variants of the original coronavirus in laboratory studies.

Zacks Equity Research

Pfizer/Valneva Lyme Disease Vaccine Candidate Enters Phase II

by Zacks Equity Research

Pfizer (PFE) and Valneva are jointly developing a vaccine candidate for Lyme disease. It is the only candidate in clinical development.

Zacks Equity Research

Novartis (NVS) & CureVac Collaborate for COVID-19 Vaccine

by Zacks Equity Research

Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.

Zacks Equity Research

Pfizer's (PFE) Lorbrena Gets FDA Nod for First-Line Lung Cancer

by Zacks Equity Research

Pfizer's (PFE) label expansion application for Lorbrena as first-line treatment for metastatic lung cancer gets approval in the United States.